| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Patrick D Skosnik, Sohee Park, Laura Dobbs, Wendi L Gardne. Affect processing and positive syndrome schizotypy in cannabis users. Psychiatry research. vol 157. issue 1-3. 2008-03-25. PMID:17897720. |
while cannabis is associated with positive syndrome schizophrenia (sz), it is unclear whether cannabinoids are also related to negative symptoms such as affective blunting. |
2008-03-25 |
2023-08-12 |
Not clear |
| Patrick D Skosnik, Sohee Park, Laura Dobbs, Wendi L Gardne. Affect processing and positive syndrome schizotypy in cannabis users. Psychiatry research. vol 157. issue 1-3. 2008-03-25. PMID:17897720. |
the lack of blunted responses during the affect erp and decreased negative subscale schizotypy scores provide evidence that the endocannabinoid theory of schizophrenia may be primarily relevant in relation to positive syndrome sz. |
2008-03-25 |
2023-08-12 |
Not clear |
| Nora Hamdani, Jean-Pierre Tabeze, Nicolas Ramoz, Jean Ades, Michel Hamon, Yves Sarfati, Claudette Boni, Philip Gorwoo. The CNR1 gene as a pharmacogenetic factor for antipsychotics rather than a susceptibility gene for schizophrenia. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 18. issue 1. 2008-03-11. PMID:17669634. |
neurobiological research suggests a significant role of the endocannabinoid system in schizophrenia vulnerability and also in the quality of response to antipsychotics. |
2008-03-11 |
2023-08-12 |
human |
| Chao Deng, Mei Han, Xu-Feng Huan. No changes in densities of cannabinoid receptors in the superior temporal gyrus in schizophrenia. Neuroscience bulletin. vol 23. issue 6. 2008-03-04. PMID:18064064. |
no changes in densities of cannabinoid receptors in the superior temporal gyrus in schizophrenia. |
2008-03-04 |
2023-08-12 |
human |
| Chao Deng, Mei Han, Xu-Feng Huan. No changes in densities of cannabinoid receptors in the superior temporal gyrus in schizophrenia. Neuroscience bulletin. vol 23. issue 6. 2008-03-04. PMID:18064064. |
in recent years, abnormal changes in the endocannabinoid system have been found in schizophrenia. |
2008-03-04 |
2023-08-12 |
human |
| Chao Deng, Mei Han, Xu-Feng Huan. No changes in densities of cannabinoid receptors in the superior temporal gyrus in schizophrenia. Neuroscience bulletin. vol 23. issue 6. 2008-03-04. PMID:18064064. |
in this study, we investigated the binding density of cannabinoid cb1 receptors in the stg of schizophrenia patients compared to control subjects. |
2008-03-04 |
2023-08-12 |
human |
| Jürgen Seifert, Sebastian Ossege, Hinderk M Emrich, Udo Schneider, Manfred Stuhrman. No association of CNR1 gene variations with susceptibility to schizophrenia. Neuroscience letters. vol 426. issue 1. 2007-12-14. PMID:17881126. |
in order to test the hypothesis that mutations in the central cannabinoid receptor-1 (cnr1) gene confer susceptibility to the development of schizophrenia, we performed an association study in a group of 104 german patients with schizophrenia and 140 healthy controls, using three polymorphisms within and flanking the coding exon of cnr1 (rs6454674, rs1049353, al136096). |
2007-12-14 |
2023-08-12 |
human |
| Martina Ballmaier, Marco Bortolato, Cristina Rizzetti, Michele Zoli, GianLuigi Gessa, Andreas Heinz, PierFranco Span. Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 32. issue 10. 2007-11-20. PMID:17299506. |
clinical and laboratory findings suggest that cannabinoids and their receptors are implicated in schizophrenia. |
2007-11-20 |
2023-08-12 |
rat |
| Martina Ballmaier, Marco Bortolato, Cristina Rizzetti, Michele Zoli, GianLuigi Gessa, Andreas Heinz, PierFranco Span. Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 32. issue 10. 2007-11-20. PMID:17299506. |
the role of cannabinoids in schizophrenia remains however poorly understood, as data are often contradictory. |
2007-11-20 |
2023-08-12 |
rat |
| Martina Ballmaier, Marco Bortolato, Cristina Rizzetti, Michele Zoli, GianLuigi Gessa, Andreas Heinz, PierFranco Span. Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 32. issue 10. 2007-11-20. PMID:17299506. |
our findings further suggest that cb1 receptor antagonism may be involved in restoring disturbed interactions between the activity of the endocannabinoid system and glutamate neurotransmitter system implied in schizophrenia. |
2007-11-20 |
2023-08-12 |
rat |
| Stefan Smesny, Timm Rosburg, Kati Baur, Nicole Rudolph, Heinrich Saue. Cannabinoids influence lipid-arachidonic acid pathways in schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 32. issue 10. 2007-11-20. PMID:17314920. |
cannabinoids influence lipid-arachidonic acid pathways in schizophrenia. |
2007-11-20 |
2023-08-12 |
Not clear |
| Stefan Smesny, Timm Rosburg, Kati Baur, Nicole Rudolph, Heinrich Saue. Cannabinoids influence lipid-arachidonic acid pathways in schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 32. issue 10. 2007-11-20. PMID:17314920. |
increasing evidence suggests modulating effects of cannabinoids on time of onset, severity, and outcome of schizophrenia. |
2007-11-20 |
2023-08-12 |
Not clear |
| Loris A Chah. TRP's: links to schizophrenia? Biochimica et biophysica acta. vol 1772. issue 8. 2007-09-28. PMID:17587552. |
in this review evidence for links between trp channels and schizophrenia with respect to neurodevelopment, dopaminergic and cannabinoid systems, thermoregulation, and sensory processes, is discussed. |
2007-09-28 |
2023-08-12 |
Not clear |
| Tomas Palomo, Richard M Kostrzewa, Richard J Beninger, Trevor Arche. Genetic variation and shared biological susceptibility underlying comorbidity in neuropsychiatry. Neurotoxicity research. vol 12. issue 1. 2007-09-18. PMID:17513198. |
genetic factors underlying alcoholism, substance abuse, antisocial and violent behaviour, psychosis, schizophrenia and psychopathy are emerging to implicate dopaminergic and cannabinoid, but also monoaminergic and glutamatergic systems through the maze of promoter genes and polymorphisms. |
2007-09-18 |
2023-08-12 |
Not clear |
| I Martínez-Gras, J Hoecnika, E Pérez-Hernández, R Rodríguez-Jiménez, G Ponce, Ma Jiménez-Arriero, J Ramos-Atance, T Palomo, G Rubi. [Endocannabinoid system and CNR1 gene polymorphisms in schizophrenia and addictive disorders]. Actas espanolas de psiquiatria. vol 35. issue 2. 2007-08-10. PMID:17401783. |
[endocannabinoid system and cnr1 gene polymorphisms in schizophrenia and addictive disorders]. |
2007-08-10 |
2023-08-12 |
Not clear |
| Johannes Rentzsch, Almut Penzhorn, Kim Kernbichler, Doris Plöckl, Ana Gómez-Carrillo de Castro, Jürgen Gallinat, Maria C Jockers-Scherüb. Differential impact of heavy cannabis use on sensory gating in schizophrenic patients and otherwise healthy controls. Experimental neurology. vol 205. issue 1. 2007-06-18. PMID:17368620. |
cannabis abuse may precipitate the onset of schizophrenia and a dysfunction of the endocannabinoid system may be involved in the pathology of schizophrenia. |
2007-06-18 |
2023-08-12 |
human |
| Belen Ferrer, Miguel Angel Gorriti, Ana Palomino, Isolde Gornemann, Yolanda de Diego, Francisco Javier Bermudez-Silva, Ainhoa Bilbao, Emilio Fernandez-Espejo, Rosario Moratalla, Miguel Navarro, Fernando Rodríguez de Fonsec. Cannabinoid CB1 receptor antagonism markedly increases dopamine receptor-mediated stereotypies. European journal of pharmacology. vol 559. issue 2-3. 2007-05-09. PMID:17291487. |
the contribution of the endocannabinoid system to dopamine-mediated disorganized behavior in schizophrenia is discussed. |
2007-05-09 |
2023-08-12 |
Not clear |
| A W Zuardi, J A S Crippa, J E C Hallak, F A Moreira, F S Guimarãe. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas. vol 39. issue 4. 2007-02-16. PMID:16612464. |
in addition, open case reports of schizophrenic patients treated with cbd and a preliminary report of a controlled clinical trial comparing cbd with an atypical antipsychotic drug have confirmed that this cannabinoid can be a safe and well-tolerated alternative treatment for schizophrenia. |
2007-02-16 |
2023-08-12 |
human |
| K Yaragudri Vinod, Basalingappa L Hungun. Cannabinoid-1 receptor: a novel target for the treatment of neuropsychiatric disorders. Expert opinion on therapeutic targets. vol 10. issue 2. 2006-09-25. PMID:16548770. |
in this article, the authors briefly review literature relating to the role played by the endocannabinoid system in various neuropsychiatric disorders, and the cb(1) receptor as a potential therapeutic target for the treatment of alcoholism, depression, anxiety and schizophrenia. |
2006-09-25 |
2023-08-12 |
Not clear |
| S R Laviolette, A A Grac. The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction. Cellular and molecular life sciences : CMLS. vol 63. issue 14. 2006-09-19. PMID:16699809. |
the roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction. |
2006-09-19 |
2023-08-12 |
Not clear |